足叶乙甙联合CAG方案治疗难治性急性髓细胞白血病

目的:观察足叶乙甙(VP16)联合CAG方案[粒细胞集落刺激因子(G-CSF) Ara-C 阿柔比星(ACLA)]治疗难治性急性髓细胞白血病(AML)的疗效和安全性。方法:对患者进行VP16联合CAG方案诱导缓解治疗。治疗过程中,监测患者临床表现、血常规、血生化和骨髓细胞学检查指标。结果:15例患者接受本方案治疗,其中男性7例,女性8例,中位年龄32岁(18~52岁)。完全缓解(CR)9例,部分缓解(PR)2例,未缓解(NR)4例。CR率60%,总反应率(CR PR)73.3%。最常见的毒副反应为骨髓抑制,其次为感染,以肺部感染最常见(发生率为33.3%)。结论:VP16联合CAG方案诱导治疗难治性AML是有效且安全的。

Study of treatment of refractory AML patients with VPl6 and CAG regimens

Objective: To evaluate the efficacy and safety of treatment of refractory AML with VP16 combining CAG regimen.Methods:Vp16 combining CAG regimen was administered to patients with refractory AML.Clinical manifestations,blood count,blood biochemical parameters and bone marrow smears were measured during the courses.Results: 15 patients,including 7 male and 8 female,were enrolled.Median age was 32(18~52) years old.9 patients reached CR,2PR and 4NR.CR rate was 60% and total response rate(CR PR) was 73.3%.The most commonly observed side effect of the regimen was bone marrow proliferation inhibition,and followed by infections,usually respiratory tract infections.Conclusions: VP16 combining CAG regimen as remission induction chemotherapy in patients with refractory AML was effective and safety.